Tharimmune (THAR) Stock Price, News & Analysis

Company Overview

Tharimmune, Inc. is a clinical-stage biotechnology company dedicated to developing novel immuno-activating therapies for life-threatening infectious, inflammatory and hemorrhagic conditions. The company employs a proprietary platform of synthetic innate immune receptor agonists, designed to harness and amplify the body’s natural defenses against bacterial infections, sepsis and related organ injuries. Tharimmune’s lead program targets acute conditions where rapid activation of innate immunity can reduce pathogen burden, curb systemic inflammation and improve clinical outcomes.

Founded in 2016 and headquartered in Seattle, Washington, Tharimmune emerged from academic collaborations with leading immunologists and infectious disease researchers. The company’s pipeline includes multiple preclinical candidates optimized for potency, safety and manufacturability. Their flagship TLR4 agonist is being advanced toward IND-enabling studies for sepsis and acute kidney injury, while additional programs focused on TLR7/8 and STING pathways seek to address multidrug-resistant pneumonia and hemorrhagic shock. Tharimmune’s synthetic molecules are designed for scalable chemical synthesis and have demonstrated robust activity in animal models.

Tharimmune maintains strategic partnerships with academic centers and contract research organizations across North America and Europe to accelerate development and manufacturing. The company’s research approach integrates immunology expertise with process chemistry, enabling rapid iteration on lead scaffolds and streamlined transition to GMP production. In parallel, Tharimmune collaborates with regulatory consultants to design adaptive clinical trial protocols and engage early with the U.S. Food and Drug Administration and the European Medicines Agency.

The leadership team at Tharimmune combines seasoned biopharma executives, infectious disease specialists and process development experts. The board and executive management draw on decades of experience from global pharmaceutical companies, academic research institutions and government agencies. Together, they guide Tharimmune’s mission to deliver first-in-class immunotherapies that address urgent unmet needs in critical care and infectious disease management.

Key Stats

• Today's Range: $1.71 to $1.80
• 50-Day Range: $1.29 to $1.94
• 52-Week Range: $0.95 to $6.39
• Volume: 18,511 shs
• Average Volume: 371,548 shs
• Market Capitalization: $4.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Strong Buy

Tharimmune Stock Analysis - MarketRank™

Tharimmune scored higher than 67% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Tharimmune has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tharimmune has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Tharimmune is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tharimmune is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tharimmune has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.15% of the float of Tharimmune has been sold short.

Short Interest Ratio / Days to Cover

Tharimmune has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tharimmune has recently increased by 107.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tharimmune does not currently pay a dividend.

Dividend Growth

Tharimmune does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.15% of the float of Tharimmune has been sold short.

Short Interest Ratio / Days to Cover

Tharimmune has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tharimmune has recently increased by 107.14%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: N/A

News Sentiment

Tharimmune has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Tharimmune this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for THAR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added Tharimmune to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Tharimmune insiders have bought more of their company's stock than they have sold. Specifically, they have bought $592,464.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.01% of the stock of Tharimmune is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.16% of the stock of Tharimmune is held by institutions.

THAR Stock Analysis - Frequently Asked Questions

How have THAR shares performed this year?

Tharimmune's stock was trading at $2.03 on January 1st, 2025. Since then, THAR stock has decreased by 14.8% and is now trading at $1.73.

How were Tharimmune's earnings last quarter?

Tharimmune, Inc. (NASDAQ:THAR) posted its earnings results on Monday, May, 12th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.15.

When did Tharimmune's stock split?

Tharimmune shares reverse split on the morning of Tuesday, May 28th 2024.The 1-15 reverse split was announced on Tuesday, May 28th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Tharimmune?

Shares of THAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tharimmune own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tharimmune investors own include Jiuzi (JZXN), Avenue Therapeutics (ATXI), Scinai Immunotherapeutics (SCNI), Adial Pharmaceuticals (ADIL), Sphere 3D (ANY), Blackboxstocks (BLBX).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:THAR
• Previous Symbol: NASDAQ:THAR
• CIK: 1861657
• Web: www.hillstreambio.com
• Phone: 908-955-3140
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tharimmune: $17.00
• High Price Target: $17.00
• Low Price Target: $17.00
• Potential Upside/Downside: +882.7%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -489.33%
• Return on Assets: -264.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.67
• Quick Ratio: 0.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.68 per share
• Price / Book: 2.54

Miscellaneous

• Outstanding Shares: 2,660,000
• Free Float: 2,395,000
• Market Cap: $4.60 million
• Optionable: Not Optionable
• Beta: 1.21